Product image of Naravela (Ethinylestradiol, Norgestimate) supplied by GNH India

Naravela

Active Ingredient:
Ethinylestradiol, Norgestimate
Origin:
EU

Naravela (Ethinylestradiol, Norgestimate)

Ethinylestradiol / Norgestimate, the active ingredient in Naravela, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH India supplies Naravela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Exeltis Healthcare S.L

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Naravela is a combined oral contraceptive used within the hormonal birth‑control pathway to prevent unintended pregnancy.

  • Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus.
  • Menstrual cycle regulation: helps achieve more regular menstrual periods.
  • Acne management: may improve hormone‑related acne in some women.

How It Works

  • Ethinylestradiol and norgestimate act synergistically to suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This prevents follicular development and ovulation. The estrogen component stabilises the endometrial lining, while the progestin component thickens cervical mucus and further alters the endometrium, reducing the likelihood of implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: temporary swelling or discomfort.
  • Spotting: irregular uterine bleeding, especially during the first cycles.
  • Mood changes: irritability or mild depressive symptoms.
  • Weight fluctuation: slight increase or decrease.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Hypertension: sudden increase in blood pressure.
  • Liver dysfunction: jaundice or abnormal liver enzymes.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Visual disturbances: sudden loss of vision or eye pain.
  • Gallbladder disease: gallstones or cholecystitis.

Precautions & Warnings

Before using Naravela, consider the following precautions:

  • Smoking: avoid if over 35 years old due to increased cardiovascular risk.
  • Cardiovascular disease: contraindicated in patients with history of stroke, myocardial infarction, or uncontrolled hypertension.
  • Liver disease: use with caution in hepatic impairment.
  • Migraine with aura: may exacerbate symptoms; discuss alternatives with a clinician.
  • Breast cancer: not recommended for active or past estrogen‑sensitive malignancies.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Naravela may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): may reduce effectiveness of anticoagulation.
  • Certain antiepileptics (e.g., carbamazepine, phenytoin): can lower contraceptive hormone levels.
  • Rifampin and other enzyme inducers: may diminish contraceptive efficacy.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., fluconazole): may increase hormone concentrations.
  • Antibiotics (e.g., tetracycline): potential minor reduction in effectiveness.
  • St. John’s Wort: may modestly decrease hormone levels.
  • Selective serotonin reuptake inhibitors (SSRIs): monitor for mood changes.

Frequently Asked Questions

Naravela is a combined oral contraceptive indicated for the prevention of unintended pregnancy in women of reproductive age. It works by inhibiting ovulation and altering cervical mucus to reduce the chance of fertilisation.

The two hormones in Naravela suppress the hypothalamic‑pituitary‑ovarian axis, preventing the surge of luteinising hormone and follicle‑stimulating hormone required for ovulation. The progestin component also thickens cervical mucus and changes the endometrial lining, making implantation unlikely.

The dosing regimen for Naravela is determined by the prescribing clinician. Typically, it is taken as a daily oral tablet following the specific cycle schedule indicated on the prescription label.

Naravela is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy. Limited data are available for breastfeeding; women should discuss risks and benefits with their healthcare provider before use.

To order Naravela, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naravela contains the same hormone classes as other combined oral contraceptives but uses the specific progestin norgestimate, which is associated with a lower incidence of androgenic side effects such as acne. Efficacy in preventing pregnancy is comparable across approved combined formulations.

Naravela tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep out of reach of children and do not use after the expiration date.

Naravela is taken orally, once daily, at the same time each day. The typical pack contains 21 active tablets followed by 7 placebo tablets, but patients should follow the schedule provided by their prescriber.

Serious risks include venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, and severe hypertension. Women with a history of clotting disorders, cardiovascular disease, or certain cancers should avoid using Naravela.

Naravela is contraindicated in women who are pregnant, have known or suspected breast cancer, active liver disease, uncontrolled hypertension, a history of thromboembolic events, or who smoke cigarettes and are over 35 years of age.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Norgestimate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT